# UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis

> **NCT01973049** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 202 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Daclatasvir
- **DRUG:** Asunaprevir
- **DRUG:** BMS-791325
- **DRUG:** Ribavirin
- **DRUG:** Placebo matching Ribavirin

## Key facts

- **NCT ID:** NCT01973049
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2014-08
- **Final completion:** 2014-11
- **Target enrollment:** 202 (ACTUAL)
- **Last updated:** 2015-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01973049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01973049, "UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01973049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*